Pharming Group 10/26/2023 Earnings Report

Pharming Group EPS Results

• Actual EPS: $0.01
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Pharming Group Revenue Results

• Actual Revenue: $66.70 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Pharming Group Announcement Details

• Date: 10/26/2023
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Pharming Group (OTCMKTS:PHGUF) is a biotechnology company headquartered in Leiden, the Netherlands, specializing in the development and commercialization of protein replacement therapies for rare diseases. Founded in 1988, the company leverages its proprietary technology platform to produce recombinant human proteins in transgenic animals, aiming to address conditions with high unmet medical need. Pharming’s flagship product is RUCONEST, a recombinant C1 esterase inhibitor indicated for the treatment and prevention of hereditary angioedema (HAE) attacks.

RUCONEST is marketed in North America, Europe and several other territories through a combination of direct sales and strategic partnerships. In addition to its core HAE franchise, Pharming is advancing a pipeline of next-generation enzyme replacement therapies and prophylactic biologics targeting rare genetic disorders and acute respiratory conditions. The company has preclinical and clinical stage programs focused on novel protein candidates designed to restore deficient or dysfunctional enzymes in patient populations.

Pharming Group serves patients and healthcare providers across the United States, the European Union and other global markets. The company maintains manufacturing operations in the Netherlands, ensuring compliance with stringent quality standards for biologic production. Pharming’s management team comprises experienced professionals in biotechnology research, regulatory affairs and commercial strategy, reinforcing its commitment to expand access to life-saving therapies for rare disease communities around the world.